Frankfurt
05.06.26 | 15:20
50,50 Euro
+5,21 % +2,50
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 48,400 | 49,800 | 06.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NOVONESIS A/S ADR Aktie jetzt für 0€ handeln | |||||
| 06.05. | Novonesis (Novozymes A/S): Trading by management and close relations of management | 37 | GlobeNewswire (USA) | ||
| 05.05. | Novozymes A/S reports Q1 results | 43 | Seeking Alpha | ||
| 05.05. | Novonesis Q1 2026 slides: 7% organic growth amid currency headwinds | 35 | Investing.com | ||
| 05.05. | Novonesis Q1 2026: Organisches Wachstum von 7 % trotz Währungsgegenwind | 19 | Investing.com Deutsch | ||
| 05.05. | Novonesis Q1 Net Profit Rises, Net Sales Up 7% Organically; Backs FY26 Outlook | 523 | AFX News | BRUSSELS (dpa-AFX) - Novonesis A/S (NVZMF.PK, NSIS_B.CO, NSIS-B.CO, NVZMF, NSIS-B) Tuesday said that its first quarter net profit rose from last year, helped by good performances by the Food... ► Artikel lesen | |
| 05.05. | Novonesis (Novozymes A/S): Interim report Q1 2026 | 575 | GlobeNewswire (Europe) | Strong start to the year with 7% organic sales growth and 37.8% adjusted EBITDA margin Ester Baiget, President & CEO:" The year started strong with 7% organic sales growth against a high comparable.... ► Artikel lesen | |
| 08.04. | Novonesis To Acquire Thailand Production Facility For Around $50 Mln | 612 | AFX News | WASHINGTON (dpa-AFX) - Novozymes A/S, Novonesis (NVZMF.PK, NSIS_B.CO, NSIS-B.CO, NVZMF, NSIS-B), a biotechnology company, on Wednesday announced an agreement to acquire a production facility... ► Artikel lesen | |
| 08.04. | Novonesis (Novozymes A/S): Novonesis expands global footprint with acquisition of production facility in Southeast Asia | 505 | GlobeNewswire (Europe) | Novonesis expands global footprint with acquisition of production facility in Southeast Asia Investment of around USD 50 million strengthens fermentation capabilities and supports the company's long-term... ► Artikel lesen | |
| 25.03. | Dividendenbekanntmachungen (25.03.2026) | 7.966 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AFYA LIMITED KYG011251066 0,656 USD 0,5648 EUR ALTRIA GROUP INC US02209S1033 1,06 USD 0,9127 EUR ATLAS ARTERIA AU0000013559 0... ► Artikel lesen | |
| 23.03. | Novonesis (Novozymes A/S): Resolutions from the Annual General Meeting 2026 | 2.197 | GlobeNewswire (Europe) | Today, the Annual General Meeting of Novonesis (Novozymes A/S) was conducted. The following resolutions were made: Approval of the audited Annual Report for 2025Approval of distribution of profit... ► Artikel lesen | |
| 23.03. | Novonesis (Novozymes A/S): Trading by management and close relations of management | 11 | GlobeNewswire (USA) | ||
| 23.03. | Novonesis & Hewlett Packard Enterprise Dividenden im global market - Ex-Tag 24.03.2026 | 41 | Wiener Börse | ||
| 16.03. | Novonesis (Novozymes A/S): Novonesis issues EUR 1.7 billion in bonds to refinance bridge facility | 724 | GlobeNewswire (Europe) | COPENHAGEN, Denmark - March 16, 2026. Novonesis has completed a EUR 1.7 billion bond issuance, with significant interest from a broad group of investors.
The transaction was primarily undertaken... ► Artikel lesen | |
| 13.03. | Novonesis (Novozymes A/S): Novonesis issues EUR 1.7 billion senior unsecured notes | 496 | GlobeNewswire (Europe) | On March 12, 2026, Novonesis, through Novozymes A/S, successfully priced and closed an aggregate principal amount of EUR 1.7 billion senior unsecured notes (the "Notes"). The issuance was completed... ► Artikel lesen | |
| 11.03. | Novonesis (Novozymes A/S): Trading by management and close relations of management | 23 | GlobeNewswire (USA) | ||
| 09.03. | Novonesis named a Great Employer to Work For in North Carolina | 17 | GlobeNewswire (USA) | ||
| 26.02. | Novonesis (Novozymes A/S): Invitation to the 2026 Annual General Meeting | 7 | GlobeNewswire (USA) | ||
| 26.02. | Novonesis (Novozymes A/S): Trading by management and close relations of management | 5 | GlobeNewswire (USA) | ||
| 26.02. | Novozymes Reports Climb In Q4 Bottom Line | 728 | AFX News | BRUSSELS (dpa-AFX) - Novozymes (NVZMF.PK) reported earnings for its fourth quarter that Increases, from the same period last yearThe company's earnings came in at EUR122.8 million, or EUR1.25... ► Artikel lesen | |
| 25.02. | Novozymes A/S Non-GAAP EPS of €1.49, revenue of €4.16B | 18 | Seeking Alpha |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,05 | -1,34 % | BioNTech und BMS melden neue Daten für Lungenkrebskandidat Pumitamig | BioNTech SE und Bristol Myers Squibb haben auf dem ASCO-Jahreskongress in Chicago erste globale Phase-2-Daten für den bispezifischen Immunmodulator Pumitamig in Kombination mit Chemotherapie bei fortgeschrittenem... ► Artikel lesen | |
| OCUGEN | 1,118 | +0,18 % | Ocugen, Inc. - 8-K, Current Report | ||
| VIKING THERAPEUTICS | 24,650 | -0,20 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| INFLARX | 1,594 | -0,44 % | InflaRx NV im freien Fall: Steht die Aktie vor einem Kursdesaster? - Meine Strategie für die kommende Handelswoche! | ||
| EDITAS MEDICINE | 2,340 | -0,43 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| GENMAB | 213,10 | -0,47 % | Genmab A/S: Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress | Twenty-three abstracts will highlight the versatility and strength of Genmab's portfolio and pipeline, including data from the comprehensive epcoritamab development program, including 4 oral... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 13,800 | +0,88 % | Improving Profitability Supports Sarepta Therapeutics Inc. (SRPT) as One of the Most Shorted Small-Cap Stocks to Buy | ||
| CARDIOL THERAPEUTICS | 0,989 | +2,17 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
30.04.2026 / 13:07 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| BASILEA | 53,90 | +0,37 % | David Veitch, CEO Basilea, im Interview | von Robert Jakob Moneycab.com: Herr Veitch, Basilea's Cresemba, ein Arzneimittel gegen Sporenpilze, macht mittlerweile weltweit rund 750 Millionen Dollar Umsatz. Wieviel davon schlägt auf die bottom... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 62,84 | -0,91 % | Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress | New data support potential use of plozasiran without dose adjustment in patients with moderate-to-severe renal or moderate hepatic impairment
Case report suggests that preconception exposure to... ► Artikel lesen | |
| TELIX PHARMACEUTICALS | 8,092 | -0,33 % | Telix Pharmaceuticals Limited: Telix and United Imaging Announce Strategic Theranostics Collaboration | Partnership to evaluate Telix's innovative precision medicine products and candidates in combination with United Imaging's advanced scanner platforms.Initial focus on TLX101-Px (Pixclara®1, Floretyrosine... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,520 | -2,80 % | Onco-Innovations Limited: Onco-Innovations Signs LOI with Nanosoft Polymers to Advance Polymer and Drug Delivery Development for the ONC010 Program | VANCOUVER, BC / ACCESS Newswire / June 5, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered... ► Artikel lesen | |
| TWIST BIOSCIENCE | 60,88 | +1,43 % | LenioBio GmbH: LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery | LenioBio GmbH, a TechBio company commercializing its ALiCE cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience Corporation. The collaboration will... ► Artikel lesen | |
| REPLIGEN | 107,40 | +3,92 % | Wolfe Research initiates Repligen stock coverage with outperform rating | ||
| UNIQURE | 23,200 | +0,87 % | uniQure Inc.: uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates | ~ Advancing FDA interactions on AMT-130 for Huntington's disease; Type B meeting scheduled for the second quarter of 2026 ~
~ Progressing AMT-130 toward expected UK regulatory submission; MAA on... ► Artikel lesen |
Das Unternehmen NOVONESIS A/S ADR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +2,50 (+5,21 %) liegt der Kurs bei 50,50 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NOVONESIS A/S ADR finden Sie auf Wallstreet Online.